Market Place
Sourcing Support
Sio Gene to File for Declare an Liquidating Distribution of $0.435 Per Share
02 Feb 2024 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
14 Feb 2023 //
GLOBENEWSWIRE
Sio Gene Therapies to dissolve after years of setbacks
16 Dec 2022 //
BIOPHARMADIVE
Sio Gene Announces Board Approval of Plan of Complete Liquidation & Dissolution
14 Dec 2022 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
14 Jun 2022 //
GLOBENEWSWIRE
Sio now asset-less after ditching UMass collab, layoffs coming
29 Apr 2022 //
FIERCEBIOTECH
Sio Gene Therapies Provides Corporate Update
27 Apr 2022 //
GLOBENEWSWIRE
Sio Gene Announces Corporate Updates and Fiscal Q3 2021 Financial Results
11 Feb 2022 //
GLOBENEWSWIRE
Sio Gene Therapies Prioritizes Lead Gene Therapy Programs
31 Jan 2022 //
GLOBENEWSWIRE
Oxford Biomedica announces update to agreement with Sio Gene Therapies
31 Jan 2022 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Successful Manufacture of AXO-Lenti-PD Gene Therapy
11 Nov 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Granting of FDA Fast Track Designation
01 Nov 2021 //
GLOBENEWSWIRE
Sio Shares Whirlwind of Updates, Including an FDA FTD
25 Oct 2021 //
BIOSPACE
Sio Gene Announces Positive Interim Safety and Biomarker Data from Ongoing Ph1/2
21 Oct 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Granting of FDA Fast Track Designation (AAV9-GLB1)
21 Oct 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Reorganization of R&D Group
21 Oct 2021 //
GLOBENEWSWIRE
Sio Gene Therapies to Present New Data at the European Society
04 Oct 2021 //
GLOBENEWSWIRE
Sio Gene Therapies to Present New Data at the European Society
04 Oct 2021 //
GLOBENEWSWIRE
Sio Gene Announces Dosing of First GM1 Patient in PI/II Study of AXO-AAV-GM1
09 Sep 2021 //
GLOBENEWSWIRE
Banking on shared experiences — and now a big investor
14 Jul 2021 //
ENDPTS
Banking on shared experiences — and now a big investor
14 Jul 2021 //
ENDPTS
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results
09 Jun 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th
28 Apr 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1
15 Mar 2021 //
GLOBENEWSWIRE
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial
03 Feb 2021 //
GLOBENEWSWIRE
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2
09 Nov 2020 //
GLOBENEWSWIRE
Axovant shares sink on manufacturing delay for Parkinson`s gene therapy
02 Nov 2020 //
BIOPHARMADIVE
Axovant shares sink on manufacturing delay for Parkinson`s gene therapy
30 Oct 2020 //
BIOPHARMADIVE
Axovant faces months of delay on lead Parkinson`s gene therapy
30 Oct 2020 //
ENDPTS
Axovant shares sink on manufacturing delay for Parkinson`s gene therapy
30 Oct 2020 //
BIOPHARMADIVE
Axovant Gene Therapies to Present AXO-Lenti-PD Program Update
29 Oct 2020 //
GLOBENEWSWIRE
Axovant`s Gene Therapy Gets Rare Pediatric Disease Status
12 Oct 2020 //
NASDAQ
Axovant Gene Receives Rare Pediatric Disease Designation for AXO-AAV-GM1
09 Oct 2020 //
GLOBENEWSWIRE
Axovant pushes on with Parkinson’s gene therapy, despite investor cynicism
07 Oct 2020 //
PHARMAPHORUM
Axovant Positive Data in small Parkinson`s trial
06 Oct 2020 //
ENDPTS
Axovant under pressure after selectively reporting gene therapy data in PD
06 Oct 2020 //
SEEKING ALPHA
Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort
05 Oct 2020 //
BIOSPACE
Axovant and Viralgen Sign Strategic Gene Therapy Partnership
15 Sep 2020 //
BIOSPACE
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica f
31 Jul 2020 //
GLOBENEWSWIRE
Axovant Completes Enrollment of Low-Dose Cohort in Ph1/2 Study of AXO-AAV-GM1
08 Jun 2020 //
GLOBENEWSWIRE
Vivek Ramaswamy’s brother, Shankar, spins out on his own, launching
13 May 2020 //
ENDPTS
Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing
15 Apr 2020 //
GLOBENEWSWIRE
AXOVANT PROVIDES BUSINESS AND OPERATIONS UPDATE DURING THE COVID-19 PANDEMIC
08 Apr 2020 //
AXOVANT
AXOVANT ANNOUNCES POSITIVE 12-MONTH DATA ON AXO-LENTI-PD AND PROVIDES UPDATES
13 Jan 2020 //
PRESS RELEASE
Axovant Provides Clinical Program Update for AXO-AAV-GM1
20 Dec 2019 //
PRESS RELEASE
Novo`s investment arm injects $67.5M in Oxford Biomedica
30 May 2019 //
ENDPTS
5 cash-hungry biotechs crowd into Nasdaq in search of a $600M-plus windfall
28 May 2019 //
ENDPTS
CEO of biotech investor Hercules Capital abandons his post in the midst
14 Mar 2019 //
ENDPTS
Axovant reports positive results from first cohort of SUNRISE-PD phase 2 trial
12 Mar 2019 //
PHARMABIZ
Axovant trumpets new clinical data after gene therapy pivot
11 Mar 2019 //
FIERCE BIOTECH
